Filing Flows › Comparisons › CTKB vs QTRX
Cytek Biosciences vs Quanterix: CTKB and QTRX compared
Cytek Biosciences is the larger company: $53.2M of revenue in its latest quarter (Q3 2026) against $32.9M for Quanterix (Q2 2026). Quanterix is growing faster (+34% against +2% a year earlier). Cytek Biosciences is more profitable, with an operating margin of -15.8% against -150.2%.
Where the money goes: CTKB and QTRX
Cytek Biosciences (CTKB) · Q3 2026
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Quanterix (QTRX) · Q2 2026
Quanterix, Q2 2026: revenue $32.9M (+34% year over year), operating margin -150.2%, net loss $48.9M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
| Cytek Biosciences (CTKB) | Quanterix (QTRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $53.2M | $32.9M |
| Revenue growth, Y/Y | +2% | +34% |
| Operating margin | -15.8% | -150.2% |
| Net earnings | −$6.1M | −$48.9M |
| Net margin | -11.5% | -148.7% |
| Operating cash flow | −$4.5M | −$5.1M |
| Market value | — | $147M |
| Analysts’ mean target | — | $3.17 |
Where the revenue comes from
Cytek Biosciences
- Product: $37.2M (70%)
- Service: $16.1M (30%)
Quanterix
- Product revenue: $23.4M (71%)
- Spatial biology: $9.3M (28%)
Questions
Which is bigger, Cytek Biosciences or Quanterix?
Cytek Biosciences is the larger company: $53.2M of revenue in its latest quarter (Q3 2026) against $32.9M for Quanterix (Q2 2026).
Is Cytek Biosciences or Quanterix growing faster?
Quanterix is growing faster (+34% against +2% a year earlier).
Which is more profitable, Cytek Biosciences or Quanterix?
Cytek Biosciences is more profitable, with an operating margin of -15.8% against -150.2%.
More: Cytek Biosciences earnings · how Cytek Biosciences makes money · Quanterix earnings · how Quanterix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.